Skip to main content
Sino Medical Sciences Technology Inc. logo

Sino Medical Sciences Technology Inc. — Investor Relations & Filings

Ticker · 688108 ISIN · CNE100003NY2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 812 across all filing types
Latest filing 2026-03-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688108

About Sino Medical Sciences Technology Inc.

https://www.sinomed.com/

Sino Medical Sciences Technology Inc. (SINOMED) specializes in the research, development, and manufacturing of high-end interventional medical devices. The company focuses on cardiovascular, neurovascular, and structural heart disease treatments. Its core product portfolio includes drug-eluting stents (DES) and balloon catheters, notably the BuMA and BuMA Supreme series. SINOMED utilizes proprietary technologies, such as the eG™ coating, to improve clinical outcomes and patient safety. The company maintains a strong commitment to clinical research and international expansion, aiming to provide innovative solutions for minimally invasive procedures.

Recent filings

Filing Released Lang Actions
上海市锦天城（北京）律师事务所关于赛诺医疗科学技术股份有限公司2026年第二次临时股东会之法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (“法律意见书”) issued by an external law firm regarding the convening, valid notice, attendance, and voting procedures of an extraordinary shareholders’ meeting of the company. It contains lawyer attestation on compliance with securities and company laws, but does not itself present financial statements, vote results, or minutes, nor does it serve as proxy solicitation or a formal regulatory form (e.g., 10-K, IR). It is primarily a legal compliance certification. Under the Certification Rule and given it does not fit into any more specific category, it should be classified as a general regulatory/compliance filing (RNS).
2026-03-13 Chinese
赛诺医疗科学技术股份有限公司2026年第二次临时股东会会议资料
Capital/Financing Update Classification · 95% confidence The document is titled as meeting materials for the "2026 Second Extraordinary General Meeting" of Sino Medical Science and Technology Co., Ltd. It contains detailed information about the meeting agenda, procedures, and a specific proposal regarding a share repurchase plan. The content includes the meeting notice, voting procedures, and a detailed proposal for a share buyback program, including financial details, authorization, and risk disclosures. The document is not a report of financial results or an earnings release, nor is it a regulatory announcement or a proxy solicitation. It is a comprehensive set of materials prepared for a shareholders' meeting, specifically an extraordinary general meeting (EGM), focusing on a capital/financing update (share repurchase). Given the detailed nature of the proposal and meeting materials, this fits best under the category of Capital/Financing Update (CAP). The document length (9561 characters) supports it being a full meeting material rather than a brief announcement. Therefore, the classification is CAP with high confidence.
2026-03-09 Chinese
赛诺医疗科学技术股份有限公司关于回购股份事项股东会股权登记日前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Sino Medical Science and Technology Co., Ltd. regarding the record date for shareholders' equity registration related to a share repurchase plan. It includes detailed information about the top ten shareholders and top ten unrestricted shareholders as of the record date. The document references a board meeting approving a share repurchase plan and an upcoming extraordinary shareholders meeting to discuss the repurchase. The content focuses on shareholding details and the share repurchase event, which aligns with announcements about the company buying back its own shares. The document length is 1608 characters, which is relatively short but contains substantive shareholding data related to a share repurchase. Therefore, it is best classified as a Transaction in Own Shares (POS) filing rather than a simple announcement or regulatory filing.
2026-03-09 Chinese
赛诺医疗2026年第一次临时股东大会见证法律意见
Regulatory Filings Classification · 10% confidence The provided document is a legal opinion letter (“法律意见书”) issued by a law firm concerning the procedural validity and voting outcomes of the company’s 2026 first extraordinary general meeting of shareholders. It is not the meeting notice or proxy solicitation itself, nor is it the actual voting results announcement in isolation, but rather a compliance/legal opinion filed with regulators. It does not contain substantive financial statements, audit reports, or management presentations. Therefore it is best classified under the fallback category for miscellaneous regulatory filings: RNS (Regulatory Filings).
2026-03-02 Chinese
赛诺医疗科学技术股份有限公司2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2026 first extraordinary shareholders meeting of Sino Medical Technology Co., Ltd. It includes information about the meeting date, location, attendance, voting results on specific proposals, and legal witness statements. The content focuses on the voting outcomes and procedural compliance of the shareholders meeting, which is typical of a Declaration of Voting Results & Voting Rights Announcements. The document is not a full annual or interim report, nor is it a proxy solicitation or management report. It is not a brief announcement of a report publication but a substantive disclosure of voting results. Therefore, the appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements). The document length is 2357 characters, which is consistent with a detailed voting results announcement rather than a full report.
2026-03-02 Chinese
赛诺医疗科学技术股份有限公司2025年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled '2025 年度业绩快报公告' which translates to '2025 Annual Performance Express Report Announcement'. It contains preliminary unaudited financial data for the full year 2025, including revenue, profit, net income, and other key financial metrics compared to the previous year. The document explicitly states that the data is preliminary and unaudited, and that the final audited data will be disclosed in the 2025 Annual Report. The length of the document is 2582 characters, which is relatively short and typical for a performance express report or earnings release rather than a full annual report. The document does not contain full audited financial statements or detailed management discussion and analysis, but rather a summary of key financial results and explanations for changes. This matches the characteristics of an Earnings Release (ER) rather than a full Annual Report (10-K) or Interim Report (IR). Therefore, the appropriate classification is Earnings Release (ER). FY 2025
2026-02-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.